RC1012
/ Ruichuang Bio
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
December 03, 2023
Increase of Dnts Correlated with Clinic Outcome after Allogeneic DNT Cells Infusion in r/r AML Patients
(ASH 2023)
- P1 | "Here, we reported our ongoing phase I clinical trial of RC1012 injection (allogeneic DNT cells) in patients with r/r AML (NCT05471323)...After lymphodepleting chemotherapy with fludarabine and cyclophosphamide, each patient received three infusions of HLA-mismatched DNT cells at 1... Allogeneic DNTs therapy are safe in clinical treatment and can reduce tumor burden after infusion with the increase of patient's DNT cells in complete remission and partial remission patients. These findings warrant the allogeneic DNTs as a novel adjuvant therapy with allo-HSCT to enhance the treatment efficacy in r/r AML. The finding of TIGIT, PD-1, CD57 molecules were increased on patients' T cells indicated that the combination of DNTs with immune checkpoint inhibitors may further improve the DNTs efficacy in r/r AML patients."
Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Oncology • Transplantation • B3GAT1 • CD4 • CD8 • TIGIT
May 19, 2023
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
(clinicaltrials.gov)
- P1/2 | N=72 | Recruiting | Sponsor: Guangdong Ruishun Biotech Co., Ltd | Active, not recruiting ➔ Recruiting
Enrollment open • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation
May 19, 2023
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Guangdong Ruishun Biotech Co., Ltd | Trial primary completion date: Dec 2022 ➔ Dec 2023
Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
May 15, 2023
RC1012 Injection (Allo-DNT Cells) for the Prevention of Relapse in AML Patients After Allo-HSCT
(clinicaltrials.gov)
- P1/2 | N=72 | Active, not recruiting | Sponsor: Guangdong Ruishun Biotech Co., Ltd
New P1/2 trial • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation
August 05, 2022
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Guangdong Ruishun Biotech Co., Ltd | Active, not recruiting ➔ Recruiting
Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
July 26, 2022
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
(clinicaltrials.gov)
- P1 | N=36 | Active, not recruiting | Sponsor: Guangdong Ruishun Biotech Co., Ltd | Recruiting ➔ Active, not recruiting
Enrollment closed • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
July 23, 2022
Phase I Clinical Trial of RC1012 Injection in Patients With r/r AML
(clinicaltrials.gov)
- P1 | N=36 | Recruiting | Sponsor: Guangdong Ruishun Biotech Co., Ltd
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology
June 22, 2021
Profiling Pharmacokinetics of DNT cells and Cytokines via a Single Intravenous Administration in NSG Mice.
(PubMed, Biopharm Drug Dispos)
- "Total 4x10 cells of RC1012 injection per mice were intravenously infused...Cytokines were significantly increased in vitro (4 h) and in vivo (3h). DNT cells were distributed into the lung, liver, heart, and kidney earlier, and re-distributed to lymphocyte homing spleen and bone marrow, which seemed to frame in a two-compartment PK model but more data needed to confirm, and the clearance of DNT cells fell in the first-order kinetics."
Journal • PK/PD data • Preclinical • IFNG • IL10 • IL1B • IL2 • IL4 • IL6 • NOTCH2 • TNFA
1 to 8
Of
8
Go to page
1